Retatrutide (LY3437943) is an investigational weekly injection that simultaneously activates three metabolic hormone receptors — GLP-1, GIP, and glucagon — producing the largest weight loss ever recorded in a pharmaceutical obesity trial.
What it does
Retatrutide works by mimicking three gut and pancreatic hormones at once. The first two targets are familiar from existing drugs: GLP-1 receptors (activated by semaglutide and tirzepatide) suppress appetite and slow gastric emptying, while GIP receptors (also hit by tirzepatide) amplify insulin secretion and help remodel fat tissue Kyung 2025. The third target — the glucagon receptor (GcgR) — is what sets retatrutide apart from everything currently approved.
Glucagon is typically thought of as a hormone that raises blood sugar, but activating its receptor in the liver does something metabolically useful at the right dose: it drives hepatic lipid oxidation (the liver burning fat for fuel), increases thermogenesis (heat production from calorie burning), raises resting energy expenditure, and promotes ketogenesis S 2025. In plain terms, the glucagon component makes the body burn more calories even at rest — a catabolic (breakdown-promoting) drive that works alongside, not against, the insulin-amplifying effects of GLP-1 and GIP Mohammed 2025.
The result is a three-way metabolic intervention: eat less (GLP-1), process nutrients better (GIP), and burn more (GcgR). That combination explains why retatrutide's Phase 2 weight-loss numbers exceed anything seen with a single- or dual-agonist drug S 2025 Kyung 2025.
What the evidence shows
Weight loss in obesity One Phase 2 RCT (~338 participants); Phase 3 trials (TRIUMPH program) underway
The pivotal Phase 2 trial showed dose-dependent weight loss reaching approximately 24% of body weight at 48 weeks with the 12 mg dose — a figure that exceeds published Phase 3 results for both semaglutide (~15%) and tirzepatide (~22%) S 2025 Mohammed 2025. Patients in that trial reported meaningful reductions in hunger and improved relationship with food, with qualitative research confirming that appetite suppression was perceived as the dominant benefit A 2025. The TRIUMPH registrational Phase 3 program is now evaluating retatrutide across obesity, obstructive sleep apnea, and knee osteoarthritis Kathryn 2026. Until those results read out, the 24% figure — though striking — comes from a single trial not powered for cardiovascular outcomes.
Type 2 diabetes and glycemic control Phase 2 data included diabetic subgroups; no dedicated diabetes outcomes trial completed
The Phase 2 trial enrolled participants with and without type 2 diabetes and showed robust HbA1c reductions alongside weight loss, consistent with the GLP-1 and GIP mechanisms shared with approved agents S 2025 Alberto 2025. The glucagon receptor agonism raises a theoretical concern about hepatic glucose output, but at the doses tested the net glycemic effect remained favorable, likely because GLP-1-driven insulin secretion offsets any glucagon-mediated glucose rise Kyung 2025. Dedicated glycemic efficacy trials have not yet reported.
Chronic kidney disease Ongoing Phase 3 trial (TRANSCEND-CKD); no efficacy results yet
The TRANSCEND-CKD trial is enrolling patients with obesity and chronic kidney disease (CKD) to assess whether retatrutide's metabolic effects translate to kidney-protective benefits, following the pattern seen with GLP-1 agents like semaglutide L 2025. Pharmacokinetic work in participants with impaired renal function has already been conducted to understand dosing adjustments needed in this population NCT05611957. Results are pending.
Metabolic effects in non-Western populations Phase 2 trial in Chinese participants with overweight/obesity; results pending
A dedicated trial in Chinese participants with obesity or overweight is underway NCT05548231, reflecting both regulatory requirements in China and the recognition that body composition, metabolic risk thresholds, and drug response can differ across ethnic groups. No efficacy data from this cohort have been published.
How it's used
In the Phase 2 trial, retatrutide was administered as a subcutaneous (under the skin) injection once weekly. Dosing followed an escalation schedule starting at 2 mg/week to reduce gastrointestinal side effects, advancing through 4 mg and 8 mg, up to 12 mg/week at the highest tested dose S 2025 NCT03841630. The half-life is approximately 6 days, which supports weekly dosing with stable blood levels. Injections were taken on the same day each week. In self-reported protocols outside trials, users have mirrored this escalation approach, though no standardized self-administration protocol exists. Retatrutide is not approved and is not commercially available as of mid-2025.
Side effects and safety
The side-effect profile closely mirrors tirzepatide and semaglutide. In Phase 2, the most common adverse events were gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort — all more frequent at higher doses and during escalation phases Ehab 2025 S 2025. A modest increase in resting heart rate has been observed, consistent with GLP-1 class effects. Injection-site reactions were mild and transient NCT03841630.
More serious concerns include pancreatitis (reported rarely across the GLP-1 class) and a theoretical risk of thyroid C-cell tumors based on rodent data — the same class warning carried by semaglutide and tirzepatide Mohammed 2025. Severe hypoglycemia is a risk primarily when retatrutide is combined with insulin or sulfonylureas. The glucagon receptor component adds a layer of unknowns not present with dual agonists: long-term effects on hepatic metabolism, bone density (glucagon has receptor expression in bone), and cardiovascular outcomes have not been established in large trials. The TRIUMPH Phase 3 program will be the first to generate that data Kathryn 2026. Absolute contraindications include personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, pregnancy, and prior severe pancreatitis.
Bottom line
Retatrutide's Phase 2 weight-loss signal — roughly 24% body weight at 48 weeks — is the largest ever reported for a pharmacological obesity treatment, and the glucagon receptor mechanism provides a plausible biological explanation S 2025 Kyung 2025. The evidence base is currently one Phase 2 trial; Phase 3 cardiovascular and renal outcomes data are years away. For anyone tracking the obesity pharmacology space, this is the most closely watched pipeline compound; for anyone considering use, it remains investigational with meaningful unknowns around long-term safety.